Skip to main content

Mindset Pharma discusses decision to expand into non-hallucinogenic drug discovery

Mindset Pharma CEO James Lanthier joins Proactive's Natalie Stoberman to discuss the company's latest update to expand into non-hallucinogenic therapeutic drug discovery.

Lanthier says Mindset has been one of the first biotech companies in the psychedelic space to apply state-of-the-art medicinal chemistry and behavioural pharmacology techniques to novel scaffolds of psychedelic drugs with the goal of discovering new medicines.

He adds that the company has been working towards discovering novel psychedelic-inspired non-hallucinogenic drug candidates and has found multiple candidates with a promising preclinical profile.

Contact Details

Proactive Canada

+1 604-688-8158

na-editorial@proactiveinvestors.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  201.15
+2.36 (1.19%)
AAPL  263.88
+8.10 (3.17%)
AMD  203.08
-4.24 (-2.05%)
BAC  52.74
+0.19 (0.36%)
GOOG  302.82
-3.20 (-1.05%)
META  639.29
-0.48 (-0.08%)
MSFT  396.86
-4.46 (-1.11%)
NVDA  184.97
+2.16 (1.18%)
ORCL  153.97
-6.17 (-3.85%)
TSLA  410.63
-6.81 (-1.63%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.